Dr Richard Seabrook joins Elizabeth Blackwell Institute as Advisor on Business Development
22 January 2018
The University’s Elizabeth Blackwell Institute for Health Research (EBI) welcomed Dr Richard Seabrook MBA as its new Advisor on Business Development this month.
Dr Seabrook will provide guidance to support the growth of partnerships and alliances with industry across the health arena at the University of Bristol. He will lead the EBI’s engagement with small and medium-sized enterprises, investors and major companies for the translation of new health interventions. He will also focus on identifying new opportunities to translate fundamental health research across the University into commercial impact.
Dr Seabrook’s previous roles include Head of Business Development at the Wellcome Trust, where he saw over 30 of its programmes progress to the clinic or to product approval stage and was the architect of the Trust’s £200-million Seeding Drug Discovery fund. He has also been a strategic advisor for the Royal Academy of Engineering and the Engineering and Physical Sciences Research Council. Currently he runs his own advisory business, 360Biomedical, and is a Senior Advisor for the Medicines Discovery Catapult and the Wellcome Trust.
Dr Seabrook said: ‘I’m very much looking forward to working with the research and clinical faculties here at Bristol. I am sure collectively through our translational efforts we will both advance important science and create new health interventions of commercial or global health potential.’
The Elizabeth Blackwell Institute brings together researchers from many disciplines to work on innovative ways to deliver better health for all. The Institute is co-funded by the Wellcome Trust and the University. The Institute identifies cutting-edge projects and groups, and provides them with support for pivotal stages in the research process, including access to specialist expertise or resources.